Peter Klivenyi

List of Publications by Year in descending order

169 papers	8,905 citations	87723 38 h-index	43802 91 g-index
182 all docs	182 docs citations	182 times ranked	10831 citing authors

#	Article	IF	Citations
1	Realâ€world user experience with seizure detection wearable devices in the home environment. Epilepsia, 2023, 64, .	2.6	8
2	Webâ€based decision support system for patientâ€tailored selection of antiseizure medication in adolescents and adults: An external validation study. European Journal of Neurology, 2022, 29, 382-389.	1.7	7
3	Functional Connectivity Lateralisation Shift of Resting State Networks is Linked to Visuospatial Memory and White Matter Microstructure in Relapsingâ€“Remitting Multiple Sclerosis. Brain Topography, 2022, 35, 268-275.	0.8	3
4	Connection between microstructural alterations detected by diffusion MRI and cognitive dysfunction in MS: A model-free analysis approach. Multiple Sclerosis and Related Disorders, 2022, 57, 103442.	0.9	1
5	Factors affecting postural instability after more than one-year bilateral subthalamic stimulation in Parkinsonâ€™s disease: A cross-sectional study. PLoS ONE, 2022, 17, e0264114.	1.1	3
6	Do Hungarian multiple sclerosis care units fulfil international criteria?. PLoS ONE, 2022, 17, e0264328.	1.1	4
7	Emerging Biomarkers of Multiple Sclerosis in the Blood and the CSF: A Focus on Neurofilaments and Therapeutic Considerations. International Journal of Molecular Sciences, 2022, 23, 3383.	1.8	9
8	Re-analysis of the Hungarian amyotrophic lateral sclerosis population and evaluation of novel ALS genetic risk variants. Neurobiology of Aging, 2022, 116, 1-11.	1.5	3
9	What is the impact of catechol-O-methyltransferase (COMT) on Parkinsonâ€™s disease treatment?. Expert Opinion on Pharmacotherapy, 2022, 23, 1123-1128.	0.9	11
10	Proteomics in Multiple Sclerosis: The Perspective of the Clinician. International Journal of Molecular Sciences, 2022, 23, 5162.	1.8	15
11	Rare co-occurrence of multiple sclerosis and Wilsonâ€™s disease â€“ case report. BMC Neurology, 2022, 22, 178.	0.8	0
12	Neuronal and glial CSF biomarkers in multiple sclerosis: a systematic review and meta-analysis. Reviews in the Neurosciences, 2021, 32, 573-595.	1.4	38
13	Genetic epidemiological characteristics of a Hungarian subpopulation of patients with Huntingtonâ€™s disease. BMC Neurology, 2021, 21, 79.	0.8	0
14	NEAT1 on the Field of Parkinsonâ€™s Disease: Offense, Defense, or a Player on the Bench?. Journal of Parkinson's Disease, 2021, 11, 123-138.	1.5	11
15	Cuprizone markedly decreases kynurenic acid levels in the rodent brain tissue and plasma. Heliyon, 2021, 7, e06124.	1.4	7
16	Eye-tracking-aided characterization of saccades and antisaccades in SYNE1 ataxia patients: a pilot study. BMC Neuroscience, 2021, 22, 7.	0.8	1
17	Two Classes of T1 Hypointense Lesions in Multiple Sclerosis With Different Clinical Relevance. Frontiers in Neurology, 2021, 12, 619135.	1.1	4
18	The Effects of Bilateral Theta-burst Stimulation on Executive Functions and Affective Symptoms in Major Depressive Disorder. Neuroscience, 2021, 461, 130-139.	1.1	5

#	Article	IF	Citations
19	Gene variants and expression changes of SIRT1 and SIRT6 in peripheral blood are associated with Parkinsonâ€™s disease. Scientific Reports, 2021, 11, 10677.	1.6	11
20	The ARCA Registry: A Collaborative Global Platform for Advancing Trial Readiness in Autosomal Recessive Cerebellar Ataxias. Frontiers in Neurology, 2021, 12, 677551.	1.1	15
21	Hereditary and non-hereditary etiologies associated with extensive brain calcification: case series. Metabolic Brain Disease, 2021, 36, 2131-2139.	1.4	1
22	Editorial: Antiplatelet Agents in Stroke Prevention. Frontiers in Neurology, 2021, 12, 762060.	1.1	2
23	Voxel-based asymmetry of the regional gray matter over the inferior temporal gyrus correlates with depressive symptoms in medicated patients with major depressive disorder. Psychiatry Research - Neuroimaging, 2021, 317, 111378.	0.9	8
24	Kynurenic acid and kynurenine aminotransferase are potential biomarkers of early neurological improvement after thrombolytic therapy: A pilot study. Advances in Clinical and Experimental Medicine, 2021, 30, 0-0.	0.6	0
25	Relationships of Ischemic Stroke Occurrence and Outcome with Gene Variants Encoding Enzymes of Tryptophan Metabolism. Biomedicines, 2021, 9, 1441.	1.4	1
26	Rare complication of West Nile viral encephalitis. Ideggyogyaszati Szemle, 2021, 74, 430-432.	0.4	0
27	Atypical presentation of late-onset Sandhoff disease : A case report. Ideggyogyaszati Szemle, 2021, 74, 425-429.	0.4	0
28	Predominant neurological phenotype in a Hungarian family with two novel mutations in the XPA geneâ€”case series. Neurological Sciences, 2020, 41, 125-129.	0.9	4
29	Selecting dopamine depleters for hyperkinetic movement disorders: how do we choose?. Expert Opinion on Pharmacotherapy, 2020, 21, 1-4.	0.9	6
30	Neuroprotection in Parkinsonâ€™s disease: facts and hopes. Journal of Neural Transmission, 2020, 127, 821-829.	1.4	37
31	Altered brain network function during attention-modulated visual processing in multiple sclerosis. Multiple Sclerosis Journal, 2020, 27, 135245852095836.	1.4	9
32	The assessment of possible gender-related effect of endogenous striatal alpha-tocopherol level on MPTP neurotoxicity in mice. Heliyon, 2020, 6, e04425.	1.4	1
33	Clinicopathological Relationships in an Aged Case of DOORS Syndrome With a p.Arg506X Mutation in the ATP6V1B2 Gene. Frontiers in Neurology, 2020, 11, 767.	1.1	9
34	Fixed-dose combination therapy for Parkinsonâ€™s disease with a spotlight on entacapone in the past 20 years: a reduced pill burden and a simplified dosing regime. Expert Opinion on Pharmacotherapy, 2020, 21, 2265-2278.	0.9	6
35	Connection between small vessel disease related stroke and the MTHFR C677T polymorphism in a Hungarian population. Heliyon, 2020, 6, e05305.	1.4	0
36	Non-invasive Brain Stimulation in Alzheimer's Disease and Mild Cognitive Impairmentâ€”A State-of-the-Art Review on Methodological Characteristics and Stimulation Parameters. Frontiers in Human Neuroscience, 2020, 14, 179.	1.0	35

#	Article	IF	Citations
37	Cerebellar Predominant Increase in mRNA Expression Levels of Sirt1 and Sirt3 Isoforms in a Transgenic Mouse Model of Huntingtonâ€™s Disease. Neurochemical Research, 2020, 45, 2072-2081.	1.6	4
38	Predictors of localization, outcome, and etiology of spontaneous intracerebral hemorrhages: focus on cerebral amyloid angiopathy. Journal of Neural Transmission, 2020, 127, 963-972.	1.4	10
39	Epidemiology of multiple sclerosis in Central Europe, update from Hungary. Brain and Behavior, 2020, 10, e01598.	1.0	13
40	Increased level of NEAT1 long non-coding RNA is detectable in peripheral blood cells of patients with Parkinsonâ€™s disease. Brain Research, 2020, 1730, 146672.	1.1	45
41	Neurotransmitter and tryptophan metabolite concentration changes in the complete Freundâ€™s adjuvant model of orofacial pain. Journal of Headache and Pain, 2020, 21, 35.	2.5	11
42	LÃ©gzÃ©si elÃ©gtelensÃ©ggel jÃ¡rÃ³ CANOMAD szindrÃ³ma. Ideggyogyaszati Szemle, 2020, 73, 141-144.	0.4	4
43	A longitudinally extensive H3 K27M-mutant diffuse midline glioma in an elderly patient clinically mimicking central nervous system inflammation: a case report. Folia Neuropathologica, 2020, 58, 377-385.	0.5	1
44	Late simultaneous carcinomatous meningitis, temporal bone infiltrating macro-metastasis and disseminated multi-organ micro-metastases presenting with mono-symptomatic vertigo â€“ a clinico-pathological case reporT. Ideggyogyaszati Szemle, 2020, 73, 354-360.	0.4	2
45	Comprehensive Genetic Analysis of a Hungarian Amyotrophic Lateral Sclerosis Cohort. Frontiers in Genetics, 2019, 10, 732.	1.1	31
46	Opicapone for the treatment of Parkinsonâ€™s disease: an update. Expert Opinion on Pharmacotherapy, 2019, 20, 2201-2207.	0.9	18
47	Using global team science to identify genetic parkinson's disease worldwide. Annals of Neurology, 2019, 86, 153-157.	2.8	26
48	24-Hour Near-Infrared Spectroscopy Monitoring of Acute Ischaemic Stroke Patients Undergoing Thrombolysis or Thrombectomy: A Pilot Study. Journal of Stroke and Cerebrovascular Diseases, 2019, 28, 2337-2342.	0.7	3
49	Assessment of risk factor variants of LRRK2, MAPT, SNCA and TCEANC2 genes in Hungarian sporadic Parkinsonâ€™s disease patients. Neuroscience Letters, 2019, 706, 140-145.	1.0	4
50	Angiogenin mutations in Hungarian patients with amyotrophic lateral sclerosis: Clinical, genetic, computational, and functional analyses. Brain and Behavior, 2019, 9, e01293.	1.0	10
51	The Role of Genetic Testing in the Clinical Practice and Research of Early-Onset Parkinsonian Disorders in a Hungarian Cohort: Increasing Challenge in Genetic Counselling, Improving Chances in Stratification for Clinical Trials. Frontiers in Genetics, 2019, 10, 1061.	1.1	9
52	Indoleamine 2,3-dioxygenase as a novel therapeutic target for Huntingtonâ€™s disease. Expert Opinion on Therapeutic Targets, 2019, 23, 39-51.	1.5	15
53	The effect of physical stimuli on the expression level of key elements in mitochondrial biogenesis. Neuroscience Letters, 2019, 698, 13-18.	1.0	7
54	Additional value of tau protein measurement in the diagnosis of Creutzfeldt-Jakob disease. Ideggyogyaszati Szemle, 2019, 72, 39-47.	0.4	2

#	Article	IF	Citations
55	Clinical Characteristics and Possible Drug Targets in Autosomal Dominant Spinocerebellar Ataxias. CNS and Neurological Disorders - Drug Targets, 2019, 18, 279-293.	0.8	4
56	Additional value of tau protein measurement in the diagnosis of Creutzfeldt-Jakob disease. Ideggyogyaszati Szemle, 2019, 72, 39-47.	0.4	0
57	Alzheimerâ€™s Disease: Recent Concepts on the Relation of Mitochondrial Disturbances, Excitotoxicity, Neuroinflammation, and Kynurenines. Journal of Alzheimer's Disease, 2018, 62, 523-547.	1.2	75
58	Non-motor Behavioral Alterations of PGC-1Î±-Deficient Mice â€“ A Peculiar Phenotype With Slight Male Preponderance and No Apparent Progression. Frontiers in Behavioral Neuroscience, 2018, 12, 180.	1.0	9
59	The detection of age-, gender-, and region-specific changes in mouse brain tocopherol levels via the application of different validated HPLC methods. Neurochemical Research, 2018, 43, 2081-2091.	1.6	3
60	The rs13388259 Intergenic Polymorphism in the Genomic Context of theBCYRN1Gene Is Associated with Parkinsonâ€™s Disease in the Hungarian Population. Parkinson's Disease, 2018, 2018, 1-7.	0.6	17
61	Pediatric multiple sclerosis and fulminant disease course: Features and approaches to treatment â€“ A case report and review of the literature. Journal of Clinical Neuroscience, 2018, 53, 13-19.	0.8	4
62	Effect of MPTP on mRNA expression of PGC-1Î± in mouse brain. Brain Research, 2017, 1660, 20-26.	1.1	13
63	Genetic analysis of the SOD1 and C9ORF72 genes in Hungarian patients with amyotrophic lateral sclerosis. Neurobiology of Aging, 2017, 53, 195.e1-195.e5.	1.5	17
64	The establishment of tocopherol reference intervals for Hungarian adult population using a validated HPLC method. Biomedical Chromatography, 2017, 31, e3953.	0.8	7
65	Levodopa/carbidopa intestinal gel can improve both motor and non-motor experiences of daily living in Parkinsonâ€™s disease: An open-label study. Parkinsonism and Related Disorders, 2017, 37, 79-86.	1.1	36
66	Unlike PPARgamma, neither other PPARs nor PGC-1alpha is elevated in the cerebrospinal fluid of patients with multiple sclerosis. Neuroscience Letters, 2017, 651, 128-133.	1.0	9
67	Highâ€throughput sequencing revealed a novel <scp>SETX</scp> mutation in a Hungarian patient with amyotrophic lateral sclerosis. Brain and Behavior, 2017, 7, e00669.	1.0	24
68	The Report of p.Val717Phe Mutation in the APP Gene in a Hungarian Family With Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2017, 31, 343-345.	0.6	2
69	Neurocognitive Characterization of an SCA28 Family Caused by a Novel AFG3L2 Gene Mutation. Cerebellum, 2017, 16, 979-985.	1.4	9
70	Novel AARS2 gene mutation producing leukodystrophy: a case report. Journal of Human Genetics, 2017, 62, 329-333.	1.1	29
71	Different phenotypes in identical twins with cerebrotendinous xanthomatosis: case series. Neurological Sciences, 2017, 38, 481-483.	0.9	18
72	[P2â€“250]: CEREBROSPINAL FLUID LIPIDOMIC PROFILE IN ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P708.	0.4	1

#	Article	IF	Citations
73	Investigation of vitamin D receptor polymorphisms in amyotrophic lateral sclerosis. Acta Neurologica Scandinavica, 2016, 133, 302-308.	1.0	9
74	The Role of Cerebrospinal Fluid Biomarkers in the Evolution of Diagnostic Criteria in Alzheimerâ€™s Disease: Shortcomings in Prodromal Diagnosis. Journal of Alzheimer's Disease, 2016, 53, 373-392.	1.2	7
75	L13â€…Stimulation of the PGC-1A expression in mouse brain. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A94.2-A94.	0.9	0
76	Postnatal outcome and placental blood flow after plasmapheresis during pregnancy. Journal of Maternal-Fetal and Neonatal Medicine, 2016, 30, 1-4.	0.7	8
77	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012â€“2015). Expert Opinion on Therapeutic Patents, 2016, 26, 815-832.	2.4	14
78	Genetic background of the hereditary spastic paraplegia phenotypes in Hungary â€” An analysis of 58 probands. Journal of the Neurological Sciences, 2016, 364, 116-121.	0.3	32
79	Effect of subthalamic stimulation on distal and proximal upper limb movements in Parkinson's disease. Brain Research, 2016, 1648, 438-444.	1.1	11
80	Lack of age-related clinical progression in PGC-1Î±-deficient mice â€“ implications for mitochondrial encephalopathies. Behavioural Brain Research, 2016, 313, 272-281.	1.2	11
81	Relevance of defensin Î²-2 and Î± defensins (HNP1-3) in Alzheimer's disease. Psychiatry Research, 2016, 239, 342-345.	1.7	12
82	A novel SETX gene mutation producing ataxia with oculomotor apraxia type 2. Acta Neurologica Belgica, 2016, 116, 405-407.	0.5	4
83	Independent validation of Parkinsonâ€™s disease Sleep Scale 2nd version (PDSS-2). Sleep and Biological Rhythms, 2016, 14, 63-73.	0.5	17
84	An assessment of the frequency of mutations in the GBA and VPS35 genes in Hungarian patients with sporadic Parkinsonâ€™s disease. Neuroscience Letters, 2016, 610, 135-138.	1.0	20
85	High-dose 1,25-dihydroxyvitamin D supplementation elongates the lifespan of Huntington's disease transgenic mice. Acta Neurobiologiae Experimentalis, 2016, 76, 176-181.	0.4	7
86	Histopathological comparison of Kearns-Sayre syndrome and PGC-1Î±-deficient mice suggests aÂnovel concept for vacuole formation in mitochondrial encephalopathy. Folia Neuropathologica, 2016, 1, 9-22.	0.5	15
87	Unilateral thalamic infarction causing downward gaze palsy in a patient with uncorrected tetralogy of Fallot: a case report = A lefelÃ© tekintÃ©s bÃ©nulÃ¡sÃ¡t okozÃ³ egyoldali thalamusinfarktus Fallot-tetralÃ³gia nem korrigÃ¡lt formÃ¡jÃ¡val Ã©lÅ‘ felnÅ‘ttnÃ©l: esetismertetÃ©s. Ideggyogyaszati Szemle, 2016, 69, 415-419.	0.4	0
88	Electron Transport Disturbances and Neurodegeneration: From Albert Szent-GyÃ¶rgyiâ€™s Concept (Szeged) till Novel Approaches to Boost Mitochondrial Bioenergetics. Oxidative Medicine and Cellular Longevity, 2015, 2015, 1-19.	1.9	22
89	The Genetic Link between Parkinsonâ€™s Disease and the Kynurenine Pathway Is Still Missing. Parkinson's Disease, 2015, 2015, 1-7.	0.6	8
90	The clinical manifestations of two novel SPAST mutations. Clinical Neurology and Neurosurgery, 2015, 136, 82-85.	0.6	0

#	Article	IF	Citations
91	mRNA Expression Levels of PGC-1Î± in a Transgenic and a Toxin Model of Huntingtonâ€™s Disease. Cellular and Molecular Neurobiology, 2015, 35, 293-301.	1.7	11
92	Drug-induced movement disorders. Expert Opinion on Drug Safety, 2015, 14, 877-890.	1.0	27
93	Central nervous system-specific alterations in the tryptophan metabolism in the 3-nitropropionic acid model of Huntington's disease. Pharmacology Biochemistry and Behavior, 2015, 132, 115-124.	1.3	20
94	Low dosage of rimonabant leads to anxiolytic-like behavior via inhibiting expression levels and G-protein activity of kappa opioid receptors in a cannabinoid receptor independent manner. Neuropharmacology, 2015, 89, 298-307.	2.0	15
95	Is the MDS-UPDRS a Good Screening Tool for Detecting Sleep Problems and Daytime Sleepiness in Parkinsonâ€™s Disease?. Parkinson's Disease, 2014, 2014, 1-8.	0.6	13
96	B7 costimulation and intracellular indoleamine-2,3-dioxygenase (IDO) expression in peripheral blood of healthy pregnant and non-pregnant women. BMC Pregnancy and Childbirth, 2014, 14, 306.	0.9	20
97	The role of cognitive training in the neurorehabilitation of a patient who survived a lightning strike. A case study. NeuroRehabilitation, 2014, 35, 137-146.	0.5	0
98	Glutamatergic Dysfunctioning in Alzheimer's Disease and Related Therapeutic Targets. Journal of Alzheimer's Disease, 2014, 42, S177-S187.	1.2	64
99	Neuroprotection by Kynurenine Metabolites. , 2014, , 1403-1416.		0
100	Some molecular mechanisms of dopaminergic and glutamatergic dysfunctioning in Parkinsonâ€™s disease. Journal of Neural Transmission, 2013, 120, 673-681.	1.4	16
101	Association of vitamin D receptor gene polymorphisms and Parkinson's disease in Hungarians. Neuroscience Letters, 2013, 551, 70-74.	1.0	53
102	CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimer's and Dementia, 2013, 9, 251-261.	0.4	344
103	Elevated levels of PPAR-gamma in the cerebrospinal fluid of patients with multiple sclerosis. Neuroscience Letters, 2013, 554, 131-134.	1.0	22
104	Evaluating biomarkers of neuronal degeneration and neuroinflammation in CSF of patients with multiple sclerosisâ€“osteopontin as a potential marker of clinical severity. Journal of the Neurological Sciences, 2013, 331, 38-42.	0.3	52
105	Neuropathology of Partial PGC-1Î± Deficiency Recapitulates Features of Mitochondrial Encephalopathies but Not of Neurodegenerative Diseases. Neurodegenerative Diseases, 2013, 12, 177-188.	0.8	17
106	Diffusion MRI measured white matter microstructure as a biomarker of neurodegeneration in preclinical Huntington's disease. Ideggyogyaszati Szemle, 2013, 66, 399-405.	0.4	4
107	Assessment of the role of multidrug resistance-associated proteins in MPTP neurotoxicity in mice. Ideggyogyaszati Szemle, 2013, 66, 407-14.	0.4	2
108	Manipulating Kynurenic Acid Levels in the Brain â€“ On the Edge Between Neuroprotection and Cognitive Dysfunction. Current Topics in Medicinal Chemistry, 2012, 12, 1797-1806.	1.0	20

#	Article	IF	Citations
109	Mitochondrial Disturbances, Tryptophan Metabolites and Neurodegeneration: Medicinal Chemistry Aspects. Current Medicinal Chemistry, 2012, 19, 1899-1920.	1.2	53
110	Cognitive Functions in Ataxia with Oculomotor Apraxia Type 2. Frontiers in Neurology, 2012, 3, 125.	1.1	8
111	Mitochondrial disturbances, excitotoxicity, neuroinflammation and kynurenines: Novel therapeutic strategies for neurodegenerative disorders. Journal of the Neurological Sciences, 2012, 322, 187-191.	0.3	71
112	Language deficits in pre-symptomatic Huntingtonâ€™s disease: Evidence from Hungarian. Brain and Language, 2012, 121, 248-253.	0.8	37
113	Kynurenines in Parkinsonâ€™s disease: therapeutic perspectives. Journal of Neural Transmission, 2012, 119, 275-283.	1.4	34
114	Target Identification for Stereotactic Thalamotomy Using Diffusion Tractography. PLoS ONE, 2012, 7, e29969.	1.1	28
115	Manipulating Kynurenic Acid Levels in the Brain â€“ On the Edge Between Neuroprotection and Cognitive Dysfunction. Current Topics in Medicinal Chemistry, 2012, 12, 1797-1806.	1.0	49
116	Manipulating kynurenic acid levels in the brain - on the edge between neuroprotection and cognitive dysfunction. Current Topics in Medicinal Chemistry, 2012, 12, 1797-806.	1.0	25
117	A new myelin protein, TPPP/p25, reduced in demyelinated lesions is enriched in cerebrospinal fluid of multiple sclerosis. Biochemical and Biophysical Research Communications, 2011, 409, 137-141.	1.0	22
118	Pharmacological Models of Parkinsonâ€™s Disease in Rodents. Methods in Molecular Biology, 2011, 793, 211-227.	0.4	2
119	The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimer's and Dementia, 2011, 7, 386.	0.4	354
120	Targeting the Kynurenine Pathway-Related Alterations in Alzheimer's Disease: A Future Therapeutic Strategy. Journal of Alzheimer's Disease, 2011, 24, 199-209.	1.2	26
121	Endogenous neuroprotection in chronic neurodegenerative disorders: with particular regard to the kynurenines. Journal of Cellular and Molecular Medicine, 2011, 15, 701-717.	1.6	50
122	Synthesis and biological effects of some kynurenic acid analogs. Bioorganic and Medicinal Chemistry, 2011, 19, 7590-7596.	1.4	23
123	Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntingtonâ€™s disease. Journal of Neural Transmission, 2011, 118, 865-875.	1.4	87
124	Time-course of kynurenic acid concentration in mouse serum following the administration of a novel kynurenic acid analog. Journal of Pharmaceutical and Biomedical Analysis, 2011, 55, 540-543.	1.4	12
125	Novel therapeutic strategies in Parkinsonâ€™s disease. European Journal of Clinical Pharmacology, 2010, 66, 119-125.	0.8	24
126	cNEUPRO: Novel Biomarkers for Neurodegenerative Diseases. International Journal of Alzheimer's Disease, 2010, 2010, 1-12.	1.1	16

#	Article	IF	Citations
127	Neuroprotective effects of L-carnitine in a transgenic animal model of Huntington's disease. Biomedicine and Pharmacotherapy, 2010, 64, 282-286.	2.5	33
128	Effects of valproate on the dopaminergic system in mice. Neurological Research, 2009, 31, 217-219.	0.6	7
129	Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease. Pharmacology Biochemistry and Behavior, 2009, 94, 148-153.	1.3	84
130	Neuroprotective effects of probenecid in a transgenic animal model of Huntingtonâ€™s disease. Journal of Neural Transmission, 2009, 116, 1079-1086.	1.4	20
131	Kynurenines in chronic neurodegenerative disorders: future therapeutic strategies. Journal of Neural Transmission, 2009, 116, 1403-1409.	1.4	78
132	Neuroimaging and cognitive changes during dÃ©jÃ vu. Epilepsy and Behavior, 2009, 14, 190-196.	0.9	12
133	The role of kynurenines in disorders of the central nervous system: Possibilities for neuroprotection. Journal of the Neurological Sciences, 2009, 283, 21-27.	0.3	109
134	Nonlinear Decrease over Time in N-Acetyl Aspartate Levels in the Absence of Neuronal Loss and Increases in Glutamine and Glucose in Transgenic Huntington's Disease Mice. Journal of Neurochemistry, 2008, 74, 2108-2119.	2.1	156
135	Increased glucose metabolism and ATP level in brain tissue of Huntingtonâ€™s disease transgenic mice. FEBS Journal, 2008, 275, 4740-4755.	2.2	60
136	Peripheral Kynurenine Metabolism in Focal Dystonia. Medicinal Chemistry, 2007, 3, 285-288.	0.7	2
137	Behaviour changes in a transgenic model of Huntington's disease. Behavioural Brain Research, 2006, 169, 137-141.	1.2	22
138	Mice lacking alpha-synuclein are resistant to mitochondrial toxins. Neurobiology of Disease, 2006, 21, 541-548.	2.1	185
139	Neuroprotective Effects of Oral Administration of Triacetyluridine Against MPTP Neurotoxicity. NeuroMolecular Medicine, 2005, 6, 087-092.	1.8	13
140	Kynurenine metabolism in multiple sclerosis. Acta Neurologica Scandinavica, 2005, 112, 93-96.	1.0	93
141	Effects of Mitochondrial Toxins on the Brain Amino Acid Concentrations. Neurochemical Research, 2005, 30, 1421-1427.	1.6	8
142	Neuroprotective Effects of Phenylbutyrate in the N171-82Q Transgenic Mouse Model of Huntington's Disease. Journal of Biological Chemistry, 2005, 280, 556-563.	1.6	401
143	Kynurenine metabolism in plasma and in red blood cells in Parkinson's disease. Journal of the Neurological Sciences, 2005, 239, 31-35.	0.3	83
144	Neuroprotective Effects of Phenylbutyrate Against MPTP Neurotoxicity. NeuroMolecular Medicine, 2004, 5, 235-242.	1.8	91

#	Article	IF	Citations
145	Mice deficient in dihydrolipoamide dehydrogenase show increased vulnerability to MPTP, malonate and 3â€nitropropionic acid neurotoxicity. Journal of Neurochemistry, 2004, 88, 1352-1360.	2.1	92
146	Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease. Journal of Neurochemistry, 2004, 86, 267-272.	2.1	56
147	Neuroprotective mechanisms of creatine occur in the absence of mitochondrial creatine kinase. Neurobiology of Disease, 2004, 15, 610-617.	2.1	54
148	Kynurenines in Neurodegenerative Disorders: Therapeutic Consideration. Advances in Experimental Medicine and Biology, 2004, 541, 169-183.	0.8	29
149	Additive Neuroprotective Effects of Creatine and a Cyclooxygenase 2 Inhibitor Against Dopamine Depletion in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) Mouse Model of Parkinson's Disease. Journal of Molecular Neuroscience, 2003, 21, 191-198.	1.1	74
150	Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease. Journal of Neurochemistry, 2003, 87, 272-272.	2.1	1
151	Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. Journal of Neurochemistry, 2003, 88, 576-582.	2.1	171
152	Neural subtype specification of fertilization and nuclear transfer embryonic stem cells and application in parkinsonian mice. Nature Biotechnology, 2003, 21, 1200-1207.	9.4	585
153	Alpha-Tocopherol and NADPH in the Erythrocytes and Plasma of Multiple Sclerosis Patients. European Neurology, 2003, 50, 215-219.	0.6	13
154	Malonate and 3-Nitropropionic Acid Neurotoxicity Are Reduced in Transgenic Mice Expressing a Caspase-1 Dominant-Negative Mutant. Journal of Neurochemistry, 2002, 75, 847-852.	2.1	43
155	Mice with a Partial Deficiency of Manganese Superoxide Dismutase Show Increased Vulnerability to the Mitochondrial Toxins Malonate, 3-Nitropropionic Acid, and MPTP. Experimental Neurology, 2001, 167, 189-195.	2.0	103
156	Transgenic ALS Mice Show Increased Vulnerability to the Mitochondrial Toxins MPTP and 3-Nitropropionic Acid. Experimental Neurology, 2001, 168, 356-363.	2.0	19
157	The Prevalence of Multiple Sclerosis, Distribution of Clinical Forms of the Disease and Functional Status of Patients in CsongrÃ¡d County, Hungary. European Neurology, 2001, 46, 206-209.	0.6	37
158	Inhibition of neuronal nitric oxide synthase protects against MPTP toxicity. NeuroReport, 2000, 11, 1265-1268.	0.6	59
159	N-acetyl-L-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis. NeuroReport, 2000, 11, 2491-2493.	0.6	128
160	Partial deficiency of manganese superoxide dismutase exacerbates a transgenic mouse model of amyotrophic lateral sclerosis. Annals of Neurology, 2000, 47, 447-455.	2.8	69
161	Mice Deficient in Cellular Glutathione Peroxidase Show Increased Vulnerability to Malonate, 3-Nitropropionic Acid, and 1-Methyl-4-Phenyl-1,2,5,6-Tetrahydropyridine. Journal of Neuroscience, 2000, 20, 1-7.	1.7	2,029
162	Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nature Medicine, 1999, 5, 347-350.	15.2	669

#	Article	IF	Citations
163	Nonenzymatic antioxidants of blood in multiple sclerosis. Journal of Neurology, 1999, 246, 533-539.	1.8	70
164	Novel Free Radical Spin Traps Protect against Malonate and MPTP Neurotoxicity. Experimental Neurology, 1999, 157, 120-126.	2.0	33
165	Creatine and Cyclocreatine Attenuate MPTP Neurotoxicity. Experimental Neurology, 1999, 157, 142-149.	2.0	326
166	Azulenyl Nitrone Spin Traps Protect against MPTP Neurotoxicity. Experimental Neurology, 1998, 152, 163-166.	2.0	19
167	Manganese Superoxide Dismutase Overexpression Attenuates MPTP Toxicity. Neurobiology of Disease, 1998, 5, 253-258.	2.1	138
168	Somatostatin and Alzheimer's disease. Archives of Gerontology and Geriatrics, 1995, 21, 35-41.	1.4	14
169	Genetic landscape of early-onset dementia in Hungary. Neurological Sciences, 0, , .	0.9	4